Doha: The Qatar Genome Programme (QGP), which aims at understanding the diseases that affect Qataris, will be implemented in three phases — collecting samples; analysing them and working on tailored medicine.
In its first phase, the project sequenced 3,000 samples, the second phase will collect another 3,000 samples and — analyse them, and work on tailored medicine.
The pilot phase has a sample size of 3,000 Qataris and map the Whole Genome Sequences (WGS).
The second phase will map WGS of another 3,000 Qataris, said Dr Ena Wang (pictured), Division Chief, Translational medicine, Sidra Medical and Research Centre, yesterday.
“We are moving to the second phase to sequence another 3,000 samples and we have done 400 of it as of now,” said Dr Wang, speaking on the sidelines of a symposium on ‘Functional Genomics and Beyond: nature Via Nature.’
“For sequencing genome samples we will include people with conditions such as cancer, obesity and other diseases. It will help to map the landscape of generics,” she said.
